Back Home >> CBAY
Added on - 12/28/2022
| Symbol | L / S | Swing | Alarm Price | Sector | Volume | 60 Day Volume | Earnings Date |
|---|---|---|---|---|---|---|---|
| CBAY | Long | No | 592K | 1.1Mil | N/A |
Update Required
To play the media you will need to either update your browser to a recent version or update your Flash plugin.
Yahoo News
- Gilead Sciences Announces Completion of Acquisition of CymaBay
- Investing in CymaBay Therapeutics (NASDAQ:CBAY) three years ago would have delivered you a 540% gain
- CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis
- CymaBay Therapeutics Inc. (CBAY) Reports Q4 Loss, Misses Revenue Estimates
- CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update
- The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary Cholangitis
- CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Biotech Stock Roundup: BIIB's Q4 Results, CBAY Up on GILD's Acquisition & Other Updates
- Director Janet Dorling Sells 6,000 Shares of CymaBay Therapeutics Inc (CBAY)